APA
TGTX icon

American Portfolios Advisors’s TG Therapeutics TGTX Stock Holding History

American Portfolios Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-210
Closed -$893 – 3596
2022
Q2 		$893 Hold
210
– – ﹤0.01% 3295
2022
Q1 		$2K Hold
210
– – ﹤0.01% 3224
2021
Q4 		$3.99K Hold
210
– – ﹤0.01% 2979
2021
Q3 		$6.99K Buy
210
+85
+68% +$2.63K ﹤0.01% 2711
2021
Q2 		$4.85K Buy
+125
New +$4.91K ﹤0.01% 2826

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Portfolios Advisors's TGTX Position: Q3 2022 in Review

American Portfolios Advisors sold out of TG Therapeutics (TGTX) in Q3 2022, closing a stake of 210 shares — an estimated $893 sold.

American Portfolios Advisors first reported a position in TGTX in Q2 2021 and held it in 5 quarters. The position peaked at $6.99K in Q3 2021. 183 funds tracked by Wall St. Rank hold TGTX as of Q3 2022.

  • American Portfolios Advisors reported no remaining TG Therapeutics position as of Q3 2022 after selling out during the quarter.
  • American Portfolios Advisors sold 210 TG Therapeutics shares in Q3 2022, an estimated $893.
  • American Portfolios Advisors first reported a position in TG Therapeutics in Q2 2021 and held it in 5 quarters.
  • American Portfolios Advisors's TG Therapeutics position peaked at $6.99K in Q3 2021.
  • 183 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.